Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- BAF808 - Provider product page
- Provider
- Novus Biologicals
- Product name
- Goat Polyclonal Osteopontin/OPN Antibody
- Antibody type
- Polyclonal
Submitted references Osteopontin attenuates aging-associated phenotypes of hematopoietic stem cells.
Mesenchymal stem cells from cortical bone demonstrate increased clonal incidence, potency, and developmental capacity compared to their bone marrow-derived counterparts.
Cutting edge: Role of osteopontin and integrin αv in T cell-mediated anti-inflammatory responses in endotoxemia.
Lack of requirement of osteopontin for inflammation, bone erosion, and cartilage damage in the K/BxN model of autoantibody-mediated arthritis.
Guidi N, Sacma M, Ständker L, Soller K, Marka G, Eiwen K, Weiss JM, Kirchhoff F, Weil T, Cancelas JA, Florian MC, Geiger H
The EMBO journal 2017 Apr 3;36(7):840-853
The EMBO journal 2017 Apr 3;36(7):840-853
Mesenchymal stem cells from cortical bone demonstrate increased clonal incidence, potency, and developmental capacity compared to their bone marrow-derived counterparts.
Blashki D, Murphy MB, Ferrari M, Simmons PJ, Tasciotti E
Journal of tissue engineering 2016 Jan-Dec;7:2041731416661196
Journal of tissue engineering 2016 Jan-Dec;7:2041731416661196
Cutting edge: Role of osteopontin and integrin αv in T cell-mediated anti-inflammatory responses in endotoxemia.
Inoue M, Shinohara ML
Journal of immunology (Baltimore, Md. : 1950) 2015 Jun 15;194(12):5595-8
Journal of immunology (Baltimore, Md. : 1950) 2015 Jun 15;194(12):5595-8
Lack of requirement of osteopontin for inflammation, bone erosion, and cartilage damage in the K/BxN model of autoantibody-mediated arthritis.
Jacobs JP, Pettit AR, Shinohara ML, Jansson M, Cantor H, Gravallese EM, Mathis D, Benoist C
Arthritis and rheumatism 2004 Aug;50(8):2685-94
Arthritis and rheumatism 2004 Aug;50(8):2685-94
No comments: Submit comment
No validations: Submit validation data